Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options
Daniel R. Richardson, Steven D. Green, Matthew C. Foster, Joshua F. Zeidner
Topics & Concepts
MedicineHematologyInternal medicineOncologyHypomethylating agentAzacitidineIntensive care medicineDNA methylationChemistryGene expressionBiochemistryGeneAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia Treatments